AI Terminal
Haleon PLC
M&A Activity • May 31, 2024
5111_rns_2024-05-31_62177d46-47d1-48e0-bc12-65ea0519d16f.html
M&A Activity
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7205Q
Haleon PLC
31 May 2024
Haleon plc: disposal of the ChapStick brand completed
31 May 2024: Haleon plc ("Haleon") has today announced that it has completed the disposal of the ChapStick brand to Suave Brands Company, a portfolio company of Yellow Wood Partners.
On 25 January 2024, Haleon announced that it had reached a binding agreement for the sale of the ChapStick brand to Suave Brands Company for pre-tax cash proceeds of approximately $430 million, as well as a passive minority interest in Suave Brands Company.
| Enquiries | |||
| Investors | Media | ||
| Sonya Ghobrial | +44 7392 784784 | Zo ë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Gemma Thomas | +44 7985 175048 |
| Emma White | +44 7823 523562 | ||
| Email: [email protected] | Email: [email protected] |
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DISUASVRSOUVOAR